PRKAA1 and cancer: For example, in various cancer cells, forced-activation of AMPK, either pharmacologically and genetically, could induce p53 activation [16–18] and mammalian target of rapamycin (mTOR) complex 1 (mTORC1) inhibition [19], as well as autophagy induction [20, 21] and oncogenic protein degradation [22].